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Transversemyelitis (TM)isan inﬂammatoryprocessinvolving arestrictedareaof thespinalcord.Theusualdramaticpresentation
makes TM a medical emergency. Early detection and aggressive therapy are required in order to improve the prognosis. The
association of this unique clinical phenotype and autoantibody provides circumstantial evidence that an autoimmune aetiology
might be involved. We describe two cases of TM associated with anti-Ro (SSA) autoantibodies without connective tissue disease
manifestations. The two patients were treated successfully with IV steroids and cyclophosphamide.
1.Introduction
Transverse myelitis (TM) is an inﬂammatory process involv-
ing a restricted area of the spinal cord. The usual dramatic
presentation makes TM a medical emergency. TM—as a ﬁrst
manifestation—is unusual presentation of some autoim-
mune diseases like Sjogren’s syndrome (SS) and systemic
lupus erythematosus (SLE). Typically, TM is monophasic;
however, some patients develop recurrent TM without any
known associated disease. The association between anti-
Ro antibodies and recurrent TM has been reported, which
suggests that the mechanism of spinal cord injury may
be autoimmune in nature. Early detection and aggressive
therapy are required in order to improve the prognosis [1].
2.Case1
A 43-year-old male presented with weakness in both legs
preceded by tingling sensation, back pain, but no sphincter
dysfunction. Two months earlier, he had a similar attack.
Neurological examination revealed asymmetric ﬂaccid para-
plegia (power 0/5) with areﬂexia. Funduscopic examina-
tion showed no optic neuritis. His investigations showed
positive anti-Ro (SSA) autoantibodies. Rheumatoid factor,
anti-DNA, anti-Sm, anti-La (SSB), antiribonucleoprotein
(RNP), antiphospholipid (APL), and anti-NMO antibodies
were negative. Spinal cord Magnetic Resonance Imaging
(MRI) showed enhancing hyperintense lesion involving long
segment from lower thoracic to conus medullaris conﬁrming
the diagnosis of TM on both occasions (Figures 1 and 2).
We treated him with intravenous immunoglobulin (IVIG)
at a dose of 400mg/kg/day for ﬁve days with signiﬁcant
improvement. On the second admission, the patient received
IVIG at the same dose, methylprednisolone at a dose
of 1g/day for ﬁve days followed by oral prednisolone at
1mg/kg, and IV cyclophosphamide at a dose of 500mg every
two weeks. After four weeks of treatment, his power in the
lower limbs was 4/5.
3.Case2
A 29-year-old male presented with a three-day history of
fever, low back, and neck pain, followed by rapid bilateral
lower limb weakness and retention of urine. His neurologic
examination revealed signiﬁcant neck stiﬀness and ﬂaccid
paraparesis. His investigations showed negative Anti-NMO
antibodies, positive antinuclear antibodies (ANA) at 1:640,2 Case Reports in Rheumatology
Figure 1: Focal area of high T2 signal change in lower spinal cord
from T11-T12 level.
Figure 2: Focal enhancement within posterolateral columns corre-
sponding to the area of high signal changes on T2.
as well as anti-Ro (SSA) and anti-La (SSB) auto-antibodies.
Spinal cord MRI showed a hyperintense in T2 and isointense
in T1 cord lesion involving all along its length up to
lower medulla, with no contrast enhancement conﬁrming
the diagnosis of transverse myelitis. Patient treated with IV
methyl prednisolone 1 gram for three days and IVIG for
ﬁve days. Over a period of months, he showed improvement
in sphincteric functions and could walk with minimal
assistance.
4. Discussion
Transverse myelitis (TM), a process involving the full
thickness of the spinal cord, is a rare event with an
estimated incidence of 31 per million people [2]. It is a
well-known manifestation of many autoimmune diseases.
I tw a sr e p o r t e dt oo c c u ri nS L E[ 3], SS [4], antiphospho-
lipid syndrome [5], mixed connective tissue disease [6],
scleroderma [7], ankylosing spondylitis [8], Behcet’s disease
[3], and sarcoidosis [3]. TM may occur in less than 1% of
patients with SS and 1–3% of patients with SLE [3]. An
association with SS was the most frequent (10%), followed
by sarcoidosis (5.9%), SLE (3.8%), and antiphospholipid
syndrome (1.4%) [3]. A case-control study [9] at the Johns
Hopkins Transverse Myelopathy Center between October
2001 and January 2002 demonstrated thirteen patients
with recurrent TM; ten of them found to have anti-Ro
(SSA) autoantibodies, and they had 50% response rate to
treatment with corticosteroids. The author concluded that
the presence of these antibodies might be used as a predictor
of recurrence and that they might respond to treatment with
immunosuppressive medications, as these antibodies might
beapartialexpressionofconnectivetissuedisease.Treatment
with pulse doses of corticosteroids alone may be suboptimal
as results of treatment with a combination of corticosteroids
and cyclophosphamide have been encouraging [10]. These
patients had transverse myelitis (one of them recurrent)
without any other manifestations of connective tissue dis-
eases; one of them followed for more than three years.
In conclusion, patients with idiopathic transverse myelitis
who has autoantibodies like Ro-(SSA) might be at risk for
recurrence, which we believe warrants checking for these
autoantibodies in all these patients and defend treating them
with corticosteroids and immunosuppressive therapy.
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